Market Overview

Tocagen to Report Second Quarter 2018 Financial Results on Tuesday, August 7

Share:

Tocagen to Report Second Quarter 2018 Financial Results on Tuesday, August 7

PR Newswire

SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Tocagen Inc. (NASDAQ:TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2018 financial results and business progress on Tuesday, August 7, 2018, after the close of the U.S. financial markets.

Tocagen Inc. (PRNewsfoto/Tocagen Inc.)

To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts.

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial for recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of glioma. For more information about Tocagen, visit www.tocagen.com.

Media Contact:
Pam Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com

Investor Contact:
Elizabeth Broder
Endurance Advisors
ebroder@enduranceadvisors.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-second-quarter-2018-financial-results-on-tuesday-august-7-300690486.html

SOURCE Tocagen Inc.

View Comments and Join the Discussion!